Abstract

Background: Hodgkin’s disease (HD) in HIV infected patients shows aggressive tumour behaviour including a high frequency of unfavourable histologic subtypes, advanced stage and extranodal involvement and a poor outcome. The introduction of highly active antiretroviral therapy (HAART) has opened a new prospective in the treatment of patients with HD-HIV.

Methods: We analysed the results of four consecutive prospective phase II studies carried out within the GICAT since 1988.

Results: Table 1 summarizes the results of the prospective studies.

Conclusions: Since the widespread use of HAART, CR rate is improving and OS and DFS as well. The concomitant use of HAART and chemotherapy is feasible and advisable in our experience. In the HAART era HD seems to be a more successfully treatable malignancy, although at higher incidence and probably with the same aggressive behaviour at presentation as in the pre-HAART era.

Table 1:

Results

REGIMEN# of PTSHAART + CTSTAGE III–IVCR RATEOSDFS
EBV 17 No 88% 53% 11 mos -- 
EBVP 35 No 83% 74% 16 mos 53% at 3-yrs 
STANFORD V 59 Yes 71% 81% 68% at 2-yrs 70% at 2-yrs 
VEBEP 28 Yes 68% 75% 86% at 2-yrs 90% at 2-yrs 
REGIMEN# of PTSHAART + CTSTAGE III–IVCR RATEOSDFS
EBV 17 No 88% 53% 11 mos -- 
EBVP 35 No 83% 74% 16 mos 53% at 3-yrs 
STANFORD V 59 Yes 71% 81% 68% at 2-yrs 70% at 2-yrs 
VEBEP 28 Yes 68% 75% 86% at 2-yrs 90% at 2-yrs 

Supported by ISS grants.

Author notes

Corresponding author